OrthoPediatrics (KIDS) Financials

$17.57 +0.45 (+2.63%)

Closing price 05/7/2026 04:00 PM Eastern

Extended Trading

$17.55 -0.02 (-0.11%)

As of 05/7/2026 05:41 PM Eastern

Annual Income Statements for OrthoPediatrics

This table shows OrthoPediatrics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.26	-21	-38
Consolidated Net Income / (Loss)	1.26	-21	-38
Net Income / (Loss) Continuing Operations	1.26	-21	-38
Total Pre-Tax Income	-3.69	-21	-42
Total Operating Income	-25	-27	-35
Total Gross Profit	91	111	149
Total Revenue	122	149	205
Operating Revenue	122	149	205
Total Cost of Revenue	32	37	56
Operating Cost of Revenue	32	37	56
Total Operating Expenses	116	138	184
Selling, General & Admin Expense	58	73	103
Marketing Expense	46	53	64
Research & Development Expense	8.45	11	11
Impairment Charge	3.61	0.99	1.84
Restructuring Charge	0.00	0.00	3.65
Total Other Income / (Expense), net	22	5.44	-6.92
Interest Expense	2.42	-0.20	5.85
Other Income / (Expense), net	24	5.24	-1.07
Income Tax Expense	-4.95	-0.34	-4.11
Basic Earnings per Share	$0.06	($0.92)	($1.64)
Weighted Average Basic Shares Outstanding	20.70M	22.68M	23.08M
Diluted Earnings per Share	$0.06	($0.92)	($1.64)
Weighted Average Diluted Shares Outstanding	20.95M	22.68M	23.08M
Weighted Average Basic & Diluted Shares Outstanding	22.99M	23.55M	24.29M

This table shows OrthoPediatrics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	19	-7.85	-6.81	-2.89	-4.59	-6.69	-7.81	-6.03	-7.92	-16
Consolidated Net Income / (Loss)	19	-7.85	-6.81	-2.89	-4.59	-6.69	-7.81	-6.03	-7.92	-16
Net Income / (Loss) Continuing Operations	19	-7.85	-6.81	-2.89	-4.59	-6.69	-7.81	-6.03	-7.92	-16
Total Pre-Tax Income	14	-7.90	-7.38	-3.29	-3.74	-6.90	-10	-6.05	-9.14	-16
Total Operating Income	-6.96	-8.31	-8.59	-5.59	-4.51	-8.07	-9.72	-5.67	-5.57	-14
Total Gross Profit	26	21	24	30	31	27	32	41	40	36
Total Revenue	35	31	32	40	40	38	45	53	55	53
Operating Revenue	35	31	32	40	40	38	45	53	55	53
Total Cost of Revenue	9.06	9.77	8.03	9.53	9.02	11	13	12	15	17
Operating Cost of Revenue	9.06	9.77	8.03	9.53	9.02	11	13	12	15	17
Total Operating Expenses	33	30	32	36	35	35	42	46	46	50
Selling, General & Admin Expense	15	15	17	19	18	19	25	27	26	24
Marketing Expense	12	12	13	14	14	13	14	17	17	17
Research & Development Expense	2.21	2.47	2.45	2.97	2.56	2.92	3.00	2.54	2.58	2.92
Total Other Income / (Expense), net	21	0.41	1.21	2.30	0.77	1.16	-0.61	-0.38	-3.57	-2.35
Interest Expense	0.71	-0.06	-0.21	0.29	0.02	-0.30	0.64	0.26	3.63	1.32
Other Income / (Expense), net	22	-2.22	1.00	2.59	0.79	0.86	0.02	-0.12	0.06	-1.04
Income Tax Expense	-4.14	-0.05	-0.57	-0.40	0.85	-0.21	-2.53	-0.02	-1.22	-0.34
Basic Earnings per Share	$0.88	($0.33)	($0.30)	($0.13)	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)
Weighted Average Basic Shares Outstanding	21.15M	20.70M	22.51M	22.70M	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M
Diluted Earnings per Share	$0.87	($0.32)	($0.30)	($0.13)	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)
Weighted Average Diluted Shares Outstanding	21.30M	20.95M	22.51M	22.70M	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M
Weighted Average Basic & Diluted Shares Outstanding	22.89M	22.99M	23.33M	23.35M	23.35M	23.55M	23.83M	24.21M	24.22M	24.29M

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	1.46	23	13
Net Cash From Operating Activities	-22	-27	-27
Net Cash From Continuing Operating Activities	-22	-27	-27
Net Income / (Loss) Continuing Operations	1.26	-21	-38
Consolidated Net Income / (Loss)	1.26	-21	-38
Depreciation Expense	13	17	19
Non-Cash Adjustments To Reconcile Net Income	13	13	19
Changes in Operating Assets and Liabilities, net	-49	-36	-28
Net Cash From Investing Activities	-113	42	-13
Net Cash From Continuing Investing Activities	-113	42	-13
Purchase of Property, Plant & Equipment	-10	-17	-14
Acquisitions	-40	-3.10	-23
Purchase of Investments	-110	-51	-26
Sale and/or Maturity of Investments	47	113	50
Net Cash From Financing Activities	136	7.30	53
Net Cash From Continuing Financing Activities	136	7.30	53
Repayment of Debt	-31	-0.14	-16
Issuance of Debt	31	9.42	74
Issuance of Common Equity	139	0.00	0.00
Other Financing Activities, net	-3.17	-1.98	-4.61
Effect of Exchange Rate Changes	0.62	0.63	-0.18
Cash Interest Paid	0.70	0.04	2.75

This table details how cash moves in and out of OrthoPediatrics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-1.28	-26	26	-25	0.92	21	-9.46	7.33	22	-7.12
Net Cash From Operating Activities	-6.06	-3.34	-6.46	-4.37	-8.67	-7.54	-6.69	-6.09	-10	-3.99
Net Cash From Continuing Operating Activities	-6.06	-3.34	-6.46	-4.37	-8.67	-7.54	-6.69	-6.09	-10	-3.99
Net Income / (Loss) Continuing Operations	19	-7.85	-6.81	-2.89	-4.59	-6.69	-7.81	-6.03	-7.92	-16
Consolidated Net Income / (Loss)	19	-7.85	-6.81	-2.89	-4.59	-6.69	-7.81	-6.03	-7.92	-16
Depreciation Expense	3.29	3.52	3.85	4.08	4.27	5.19	5.03	4.78	5.28	3.99
Non-Cash Adjustments To Reconcile Net Income	5.67	2.08	2.49	3.73	3.63	3.03	3.08	3.20	7.21	5.88
Changes in Operating Assets and Liabilities, net	-34	-1.10	-6.00	-9.30	-12	-9.07	-6.99	-8.04	-15	2.21
Net Cash From Investing Activities	-104	-23	32	-18	9.67	18	-3.68	20	-27	-2.41
Net Cash From Continuing Investing Activities	-104	-23	32	-18	9.67	18	-3.68	20	-27	-2.41
Purchase of Property, Plant & Equipment	-1.09	0.52	-4.94	-5.62	-3.03	-3.84	-6.46	-6.68	-1.38	0.26
Acquisitions	-32	-	0.00	-48	-4.00	49	-21	-	-25	23
Purchase of Investments	-85	-25	-	-	-	-	-	-	-	-25
Net Cash From Financing Activities	108	-0.04	-0.04	-2.04	-0.02	9.39	-0.57	-4.27	59	-0.54
Net Cash From Continuing Financing Activities	108	-0.04	-0.04	-2.04	-0.02	9.39	-0.57	-4.27	59	-0.54
Repayment of Debt	-31	-0.04	-0.04	-0.04	-0.04	-0.04	-0.57	-0.77	-15	0.57
Other Financing Activities, net	0.02	-	-	-	0.02	-	-	-	-	-1.11
Cash Interest Paid	0.45	0.19	0.01	-	0.02	0.01	0.22	0.54	0.62	1.37

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	428	439	473
Total Current Assets	227	226	237
Cash & Equivalents	8.99	31	44
Restricted Cash	1.47	1.97	1.96
Short-Term Investments	109	49	25
Accounts Receivable	25	35	42
Inventories, net	78	106	117
Prepaid Expenses	3.97	3.75	7.02
Plant, Property, & Equipment, net	34	41	51
Total Noncurrent Assets	167	171	185
Goodwill	87	84	94
Intangible Assets	80	85	81
Other Noncurrent Operating Assets	0.00	2.94	10
Total Liabilities & Shareholders' Equity	428	439	473
Total Liabilities	49	62	119
Total Current Liabilities	31	42	34
Short-Term Debt	0.14	0.15	0.16
Accounts Payable	11	13	8.91
Current Employee Benefit Liabilities	6.74	11	14
Other Current Liabilities	13	18	11
Total Noncurrent Liabilities	18	20	85
Long-Term Debt	0.76	9.91	73
Noncurrent Deferred & Payable Income Tax Liabilities	5.95	5.48	3.38
Other Noncurrent Operating Liabilities	11	4.66	8.34
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	379	377	355
Total Preferred & Common Equity	379	377	355
Total Common Equity	379	377	355
Common Stock	561	580	601
Retained Earnings	-177	-198	-236
Accumulated Other Comprehensive Income / (Loss)	-5.40	-5.53	-11

This table presents OrthoPediatrics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	430	426	435	432	437	431	489
Total Current Assets	225	225	223	226	204	194	248
Cash & Equivalents	35	35	9.71	11	22	29	51
Restricted Cash	1.45	1.48	1.60	1.59	1.96	1.96	2.00
Short-Term Investments	85	73	83	72	26	0.00	25
Accounts Receivable	26	27	34	38	36	42	43
Inventories, net	74	85	91	101	113	116	121
Prepaid Expenses	2.75	4.01	3.64	3.98	5.06	4.50	6.49
Plant, Property, & Equipment, net	36	37	40	40	49	53	55
Total Noncurrent Assets	169	164	172	166	185	183	186
Goodwill	88	84	83	81	91	91	91
Intangible Assets	81	80	88	85	89	87	85
Other Noncurrent Operating Assets	-	-	0.61	0.62	4.08	6.47	10
Total Liabilities & Shareholders' Equity	430	426	435	432	437	431	489
Total Liabilities	47	53	55	58	67	59	118
Total Current Liabilities	29	35	44	48	46	40	35
Short-Term Debt	0.14	0.15	0.15	0.15	0.15	0.16	0.16
Accounts Payable	11	17	21	23	20	17	12
Current Employee Benefit Liabilities	6.32	6.24	8.16	8.67	9.77	13	13
Other Current Liabilities	11	12	15	17	16	9.80	9.60
Total Noncurrent Liabilities	18	18	10	10	21	20	84
Long-Term Debt	0.80	0.73	0.69	0.65	10	9.78	73
Noncurrent Deferred & Payable Income Tax Liabilities	5.46	6.02	5.56	5.49	5.20	4.74	4.03
Other Noncurrent Operating Liabilities	12	11	4.00	4.05	5.43	5.38	7.21
Total Equity & Noncontrolling Interests	383	373	380	374	371	371	371
Total Preferred & Common Equity	383	373	380	374	371	371	371
Total Common Equity	383	373	380	374	371	371	371
Common Stock	559	563	575	578	583	593	597
Retained Earnings	-169	-184	-186	-191	-206	-212	-219
Accumulated Other Comprehensive Income / (Loss)	-7.10	-6.05	-7.91	-12	-6.96	-10	-6.60

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	24.72%	21.62%	37.65%
EBITDA Growth	365.28%	-134.86%	-312.07%
EBIT Growth	91.65%	-1,600.40%	-67.73%
NOPAT Growth	-40.92%	-5.32%	-30.87%
Net Income Growth	107.74%	-1,767.25%	-80.33%
EPS Growth	107.14%	-1,633.33%	-78.26%
Operating Cash Flow Growth	-66.62%	-24.26%	-0.01%
Free Cash Flow Firm Growth	-217.08%	39.91%	-20.17%
Invested Capital Growth	51.48%	17.33%	17.09%
Revenue Q/Q Growth	5.32%	4.66%	7.94%
EBITDA Q/Q Growth	-38.24%	54.74%	-114.62%
EBIT Q/Q Growth	-118.68%	13.38%	-27.96%
NOPAT Q/Q Growth	65.44%	0.90%	-20.64%
Net Income Q/Q Growth	-86.29%	5.23%	-32.97%
EPS Q/Q Growth	-84.21%	3.16%	-33.33%
Operating Cash Flow Q/Q Growth	-10.71%	-18.39%	11.62%
Free Cash Flow Firm Q/Q Growth	29.75%	-34.69%	19.14%
Invested Capital Q/Q Growth	-1.10%	4.70%	-2.36%
Profitability Metrics	-	-	-
Gross Margin	74.14%	74.80%	72.58%
EBITDA Margin	9.68%	-2.77%	-8.30%
Operating Margin	-20.77%	-17.99%	-17.10%
EBIT Margin	-1.03%	-14.46%	-17.62%
Profit (Net Income) Margin	1.03%	-14.10%	-18.47%
Tax Burden Percent	-34.10%	98.41%	90.20%
Interest Burden Percent	291.62%	99.08%	116.22%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-8.24%	-6.63%	-7.41%
ROIC Less NNEP Spread (ROIC-NNEP)	-30.29%	-4.28%	30.69%
Return on Net Nonoperating Assets (RNNOA)	8.66%	1.08%	-2.93%
Return on Equity (ROE)	0.42%	-5.55%	-10.34%
Cash Return on Invested Capital (CROIC)	-49.19%	-22.58%	-23.15%
Operating Return on Assets (OROA)	-0.35%	-4.97%	-7.91%
Return on Assets (ROA)	0.34%	-4.84%	-8.29%
Return on Common Equity (ROCE)	0.42%	-5.55%	-10.34%
Return on Equity Simple (ROE_SIMPLE)	0.33%	-5.56%	-10.67%
Net Operating Profit after Tax (NOPAT)	-18	-19	-25
NOPAT Margin	-14.54%	-12.59%	-11.97%
Net Nonoperating Expense Percent (NNEP)	22.04%	-2.35%	-38.10%
Return On Investment Capital (ROIC_SIMPLE)	-4.68%	-4.84%	-5.73%
Cost of Revenue to Revenue	25.86%	25.20%	27.42%
SG&A Expenses to Revenue	47.35%	49.28%	50.21%
R&D to Revenue	6.91%	7.33%	5.39%
Operating Expenses to Revenue	94.91%	92.79%	89.68%
Earnings before Interest and Taxes (EBIT)	-1.27	-22	-36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	12	-4.13	-17
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.40	2.01	1.58
Price to Tangible Book Value (P/TBV)	4.29	3.64	3.13
Price to Revenue (P/Rev)	7.44	5.10	2.74
Price to Earnings (P/E)	722.96	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.14%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.04	2.25	1.58
Enterprise Value to Revenue (EV/Rev)	6.47	4.62	2.75
Enterprise Value to EBITDA (EV/EBITDA)	66.81	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.03	0.21
Long-Term Debt to Equity	0.00	0.03	0.21
Financial Leverage	-0.29	-0.25	-0.10
Leverage Ratio	1.21	1.15	1.25
Compound Leverage Factor	3.53	1.14	1.45
Debt to Total Capital	0.24%	2.60%	17.10%
Short-Term Debt to Total Capital	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	0.20%	2.56%	17.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.76%	97.40%	82.90%
Debt to EBITDA	0.08	-2.44	-4.30
Net Debt to EBITDA	-10.04	17.51	-0.14
Long-Term Debt to EBITDA	0.06	-2.40	-4.29
Debt to NOPAT	-0.05	-0.54	-2.98
Net Debt to NOPAT	6.69	3.86	-0.09
Long-Term Debt to NOPAT	-0.04	-0.53	-2.98
Altman Z-Score	11.37	7.43	2.84
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.34	5.44	6.98
Quick Ratio	4.64	2.76	3.27
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-106	-64	-77
Operating Cash Flow to CapEx	-216.99%	-155.22%	-189.64%
Free Cash Flow to Firm to Interest Expense	-43.76	0.00	-13.09
Operating Cash Flow to Interest Expense	-8.98	0.00	-4.62
Operating Cash Flow Less CapEx to Interest Expense	-13.12	0.00	-7.06
Efficiency Ratios	-	-	-
Asset Turnover	0.33	0.34	0.45
Accounts Receivable Turnover	5.72	5.01	5.32
Inventory Turnover	0.47	0.41	0.50
Fixed Asset Turnover	3.89	3.95	4.47
Accounts Payable Turnover	3.09	3.15	5.21
Days Sales Outstanding (DSO)	63.79	72.91	68.62
Days Inventory Outstanding (DIO)	783.34	896.18	724.60
Days Payable Outstanding (DPO)	118.14	115.89	70.09
Cash Conversion Cycle (CCC)	728.99	853.20	723.13
Capital & Investment Metrics	-	-	-
Invested Capital	260	305	357
Invested Capital Turnover	0.57	0.53	0.62
Increase / (Decrease) in Invested Capital	88	45	52
Enterprise Value (EV)	791	687	564
Market Capitalization	909	759	561
Book Value per Share	$16.54	$16.14	$14.64
Tangible Book Value per Share	$9.26	$8.94	$7.41
Total Capital	380	387	428
Total Debt	0.91	10	73
Total Long-Term Debt	0.76	9.91	73
Net Debt	-119	-72	2.33
Capital Expenditures (CapEx)	10	17	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	76	103	133
Debt-free Net Working Capital (DFNWC)	196	185	203
Net Working Capital (NWC)	196	185	203
Net Nonoperating Expense (NNE)	-19	2.25	13
Net Nonoperating Obligations (NNO)	-119	-72	2.33
Total Depreciation and Amortization (D&A)	13	17	19
Debt-free, Cash-free Net Working Capital to Revenue	62.34%	69.05%	64.76%
Debt-free Net Working Capital to Revenue	160.27%	124.37%	99.34%
Net Working Capital to Revenue	160.15%	124.27%	99.26%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.06	($0.92)	($1.64)
Adjusted Weighted Average Basic Shares Outstanding	20.70M	22.68M	23.08M
Adjusted Diluted Earnings per Share	$0.06	($0.92)	($1.64)
Adjusted Weighted Average Diluted Shares Outstanding	20.95M	22.68M	23.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	22.99M	23.55M	24.29M
Normalized Net Operating Profit after Tax (NOPAT)	-15	-18	-21
Normalized NOPAT Margin	-12.47%	-12.13%	-10.09%
Pre Tax Income Margin	-3.02%	-14.33%	-20.48%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-0.52	0.00	-6.17
NOPAT to Interest Expense	-7.33	0.00	-4.19
EBIT Less CapEx to Interest Expense	-4.66	0.00	-8.60
NOPAT Less CapEx to Interest Expense	-11.47	0.00	-6.63
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from OrthoPediatrics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	39.36%	24.91%	34.89%	20.14%	14.37%	21.36%	41.46%	33.48%	36.53%	40.02%
EBITDA Growth	2,912.08%	-2,290.00%	-12.71%	-71.17%	-97.01%	71.19%	-24.83%	-192.64%	-140.62%	-449.63%
EBIT Growth	547.26%	-322.81%	-20.84%	-780.23%	-124.64%	31.55%	-27.79%	-93.32%	-47.89%	-109.41%
NOPAT Growth	-251.43%	-49.42%	-34.53%	-49.24%	64.80%	2.92%	-13.18%	-1.43%	-23.47%	-74.25%
Net Income Growth	943.83%	-11,000.00%	25.21%	-766.67%	-124.76%	14.74%	-14.68%	-108.91%	-72.49%	-140.16%
EPS Growth	890.91%	0.00%	36.17%	-550.00%	-122.99%	9.38%	-13.33%	-100.00%	-70.00%	-141.38%
Operating Cash Flow Growth	-546.53%	-170.53%	-53.94%	46.47%	-43.10%	-125.77%	-3.54%	-39.31%	-18.57%	47.14%
Free Cash Flow Firm Growth	-633.48%	-280.57%	-250.61%	-55.37%	70.89%	46.17%	27.67%	18.73%	-147.95%	-22.24%
Invested Capital Growth	61.02%	51.48%	56.08%	38.56%	10.82%	17.33%	25.06%	22.34%	25.56%	17.09%
Revenue Q/Q Growth	6.14%	-11.32%	1.92%	25.23%	1.04%	-5.90%	18.80%	18.16%	3.35%	-3.49%
EBITDA Q/Q Growth	387.70%	-138.11%	46.60%	129.05%	-49.49%	-467.76%	-131.35%	78.44%	77.86%	-4,876.23%
EBIT Q/Q Growth	3,332.73%	-169.70%	27.91%	60.57%	-24.32%	-93.66%	-34.60%	40.34%	4.89%	-174.21%
NOPAT Q/Q Growth	-242.14%	35.12%	-3.39%	34.98%	19.30%	-78.93%	-20.54%	41.73%	1.76%	-152.52%
Net Income Q/Q Growth	5,667.27%	-142.33%	13.28%	57.60%	-59.08%	-45.74%	-16.65%	22.75%	-31.35%	-102.92%
EPS Q/Q Growth	4,450.00%	-136.78%	6.25%	56.67%	-53.85%	-45.00%	-17.24%	23.53%	-30.77%	-105.88%
Operating Cash Flow Q/Q Growth	25.85%	44.85%	-93.39%	32.32%	-98.24%	12.99%	11.31%	8.94%	-68.73%	61.21%
Free Cash Flow Firm Q/Q Growth	-101.66%	13.27%	-7.50%	17.36%	62.22%	-60.40%	-44.45%	7.15%	-15.26%	20.92%
Invested Capital Q/Q Growth	27.10%	-1.10%	1.93%	8.14%	1.66%	4.70%	8.65%	5.78%	4.34%	-2.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	74.07%	68.48%	74.59%	75.90%	77.44%	71.02%	72.00%	77.27%	73.41%	67.53%
EBITDA Margin	52.62%	-22.61%	-11.85%	2.75%	1.37%	-5.37%	-10.45%	-1.91%	-0.41%	-21.07%
Operating Margin	-19.92%	-26.81%	-27.20%	-14.12%	-11.28%	-21.44%	-21.76%	-10.73%	-10.20%	-26.69%
EBIT Margin	43.22%	-33.97%	-24.03%	-7.57%	-9.31%	-19.16%	-21.71%	-10.96%	-10.08%	-28.65%
Profit (Net Income) Margin	53.04%	-25.32%	-21.55%	-7.30%	-11.49%	-17.79%	-17.47%	-11.42%	-14.51%	-30.51%
Tax Burden Percent	128.78%	99.39%	92.22%	87.80%	122.69%	96.93%	75.51%	99.70%	86.67%	97.93%
Interest Burden Percent	95.31%	75.00%	97.23%	109.82%	100.56%	95.80%	106.57%	104.51%	166.04%	108.74%
Effective Tax Rate	-28.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-13.99%	-10.64%	-11.43%	-5.50%	-4.05%	-7.91%	-8.27%	-4.13%	-4.12%	-11.56%
ROIC Less NNEP Spread (ROIC-NNEP)	-44.78%	-8.29%	-10.40%	-7.29%	-2.64%	-6.82%	-6.92%	-0.54%	4.96%	6.27%
Return on Net Nonoperating Assets (RNNOA)	13.23%	2.37%	2.72%	1.37%	0.71%	1.72%	1.37%	0.08%	-0.59%	-0.60%
Return on Equity (ROE)	-0.75%	-8.27%	-8.71%	-4.12%	-3.34%	-6.19%	-6.90%	-4.05%	-4.71%	-12.16%
Cash Return on Invested Capital (CROIC)	-70.92%	-49.19%	-52.69%	-40.69%	-17.09%	-22.58%	-28.82%	-26.24%	-28.85%	-23.15%
Operating Return on Assets (OROA)	13.68%	-11.35%	-8.62%	-2.71%	-3.07%	-6.58%	-8.14%	-4.43%	-4.15%	-12.86%
Return on Assets (ROA)	16.79%	-8.46%	-7.73%	-2.61%	-3.78%	-6.11%	-6.55%	-4.62%	-5.97%	-13.70%
Return on Common Equity (ROCE)	-0.75%	-8.27%	-8.71%	-4.12%	-3.34%	-6.19%	-6.90%	-4.05%	-4.71%	-12.16%
Return on Equity Simple (ROE_SIMPLE)	2.39%	0.00%	0.95%	0.26%	-5.91%	0.00%	-5.93%	-6.76%	-7.67%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.96	-5.82	-6.01	-3.91	-3.16	-5.65	-6.81	-3.97	-3.90	-9.84
NOPAT Margin	-25.65%	-18.77%	-19.04%	-9.88%	-7.89%	-15.01%	-15.23%	-7.51%	-7.14%	-18.68%
Net Nonoperating Expense Percent (NNEP)	30.80%	-2.35%	-1.03%	1.79%	-1.41%	-1.09%	-1.35%	-3.59%	-9.08%	-17.83%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.53%	-	-	-	-1.46%	-	-	-	-2.30%
Cost of Revenue to Revenue	25.93%	31.52%	25.41%	24.10%	22.56%	28.98%	28.00%	22.73%	26.59%	32.47%
SG&A Expenses to Revenue	43.25%	48.64%	54.31%	48.31%	44.96%	50.67%	55.34%	51.76%	48.19%	46.39%
R&D to Revenue	6.31%	7.98%	7.74%	7.50%	6.41%	7.77%	6.71%	4.82%	4.72%	5.54%
Operating Expenses to Revenue	93.99%	95.29%	101.79%	90.02%	88.71%	92.47%	93.76%	88.00%	83.61%	94.21%
Earnings before Interest and Taxes (EBIT)	15	-11	-7.59	-2.99	-3.72	-7.21	-9.70	-5.79	-5.50	-15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	18	-7.01	-3.74	1.09	0.55	-2.02	-4.67	-1.01	-0.22	-11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.44	2.40	2.73	2.69	2.00	2.01	1.85	1.85	1.77	1.58
Price to Tangible Book Value (P/TBV)	4.37	4.29	4.88	4.89	3.58	3.64	3.62	3.53	3.37	3.13
Price to Revenue (P/Rev)	8.06	7.44	7.81	7.46	5.26	5.10	4.24	3.91	3.46	2.74
Price to Earnings (P/E)	101.94	722.96	286.71	1,023.92	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.98%	0.14%	0.35%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.10	3.04	3.44	3.24	2.28	2.25	1.95	1.90	1.78	1.58
Enterprise Value to Revenue (EV/Rev)	7.02	6.47	6.98	6.78	4.67	4.62	4.00	3.79	3.43	2.75
Enterprise Value to EBITDA (EV/EBITDA)	42.53	66.81	79.74	106.43	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	120.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.03	0.03	0.03	0.20	0.21
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.03	0.03	0.03	0.20	0.21
Financial Leverage	-0.30	-0.29	-0.26	-0.19	-0.27	-0.25	-0.20	-0.15	-0.12	-0.10
Leverage Ratio	1.21	1.21	1.24	1.26	1.14	1.15	1.16	1.15	1.24	1.25
Compound Leverage Factor	1.16	0.91	1.20	1.38	1.14	1.10	1.24	1.20	2.05	1.36
Debt to Total Capital	0.25%	0.24%	0.23%	0.22%	0.21%	2.60%	2.71%	2.61%	16.38%	17.10%
Short-Term Debt to Total Capital	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%
Long-Term Debt to Total Capital	0.21%	0.20%	0.19%	0.18%	0.17%	2.56%	2.67%	2.57%	16.35%	17.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.75%	99.76%	99.77%	99.78%	99.79%	97.40%	97.29%	97.39%	83.62%	82.90%
Debt to EBITDA	0.05	0.08	0.08	0.10	-0.09	-2.44	-2.04	-1.39	-9.18	-4.30
Net Debt to EBITDA	-6.30	-10.04	-9.49	-10.76	9.13	17.51	7.80	2.93	0.68	-0.14
Long-Term Debt to EBITDA	0.04	0.06	0.06	0.08	-0.07	-2.40	-2.01	-1.37	-9.16	-4.29
Debt to NOPAT	-0.02	-0.05	-0.05	-0.04	-0.04	-0.54	-0.53	-0.51	-3.58	-2.98
Net Debt to NOPAT	2.35	6.69	5.61	4.56	4.40	3.86	2.02	1.07	0.27	-0.09
Long-Term Debt to NOPAT	-0.02	-0.04	-0.04	-0.03	-0.03	-0.53	-0.52	-0.50	-3.57	-2.98
Altman Z-Score	12.40	11.29	11.68	11.44	7.89	7.54	6.26	7.02	3.57	2.98
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.81	7.34	6.39	5.04	4.72	5.44	4.45	4.90	7.17	6.98
Quick Ratio	5.09	4.64	3.82	2.87	2.51	2.76	1.83	1.79	3.43	3.27
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-109	-94	-101	-84	-32	-51	-73	-68	-78	-62
Operating Cash Flow to CapEx	-556.29%	0.00%	-130.79%	-77.77%	-286.58%	-196.64%	-103.56%	-91.14%	-744.32%	0.00%
Free Cash Flow to Firm to Interest Expense	-153.26	0.00	0.00	-284.36	-1,503.93	0.00	-114.87	-260.31	-21.55	-46.95
Operating Cash Flow to Interest Expense	-8.56	0.00	0.00	-14.87	-412.81	0.00	-10.50	-23.34	-2.83	-3.02
Operating Cash Flow Less CapEx to Interest Expense	-10.09	0.00	0.00	-34.00	-556.86	0.00	-20.64	-48.95	-3.21	-2.82
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.32	0.33	0.36	0.36	0.33	0.34	0.37	0.40	0.41	0.45
Accounts Receivable Turnover	5.24	5.72	5.83	4.63	4.45	5.01	5.13	4.61	4.71	5.32
Inventory Turnover	0.44	0.47	0.47	0.46	0.42	0.41	0.42	0.43	0.45	0.50
Fixed Asset Turnover	3.57	3.89	3.84	3.58	3.71	3.95	3.78	3.74	3.99	4.47
Accounts Payable Turnover	2.88	3.09	2.23	2.05	2.17	3.15	2.30	2.35	2.92	5.21
Days Sales Outstanding (DSO)	69.68	63.79	62.60	78.92	81.97	72.91	71.17	79.10	77.43	68.62
Days Inventory Outstanding (DIO)	826.61	783.34	781.28	794.69	876.47	896.18	859.42	851.67	809.55	724.60
Days Payable Outstanding (DPO)	126.72	118.14	163.96	177.93	168.03	115.89	158.43	155.64	125.14	70.09
Cash Conversion Cycle (CCC)	769.56	728.99	679.91	695.67	790.41	853.20	772.17	775.12	761.84	723.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	263	260	265	286	291	305	331	350	366	357
Invested Capital Turnover	0.55	0.57	0.60	0.56	0.51	0.53	0.54	0.55	0.58	0.62
Increase / (Decrease) in Invested Capital	100	88	95	80	28	45	66	64	74	52
Enterprise Value (EV)	815	791	910	929	664	687	647	664	651	564
Market Capitalization	936	909	1,018	1,023	747	759	687	685	656	561
Book Value per Share	$18.90	$16.54	$16.23	$16.30	$16.03	$16.14	$15.74	$15.58	$15.32	$14.64
Tangible Book Value per Share	$10.56	$9.26	$9.08	$8.98	$8.95	$8.94	$8.07	$8.15	$8.05	$7.41
Total Capital	384	380	374	381	375	387	381	381	444	428
Total Debt	0.94	0.91	0.87	0.84	0.80	10	10	9.94	73	73
Total Long-Term Debt	0.80	0.76	0.73	0.69	0.65	9.91	10	9.78	73	73
Net Debt	-121	-119	-108	-94	-83	-72	-39	-21	-5.39	2.33
Capital Expenditures (CapEx)	1.09	-0.52	4.94	5.62	3.03	3.84	6.46	6.68	1.38	-0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	74	76	81	84	94	103	108	123	136	133
Debt-free Net Working Capital (DFNWC)	196	196	190	179	178	185	158	154	214	203
Net Working Capital (NWC)	196	196	190	179	178	185	158	154	214	203
Net Nonoperating Expense (NNE)	-28	2.03	0.79	-1.02	1.44	1.04	1.00	2.06	4.02	6.23
Net Nonoperating Obligations (NNO)	-121	-119	-108	-94	-83	-72	-39	-21	-5.39	2.33
Total Depreciation and Amortization (D&A)	3.29	3.52	3.85	4.08	4.27	5.19	5.03	4.78	5.28	3.99
Debt-free, Cash-free Net Working Capital to Revenue	64.06%	62.34%	61.85%	61.50%	66.41%	69.05%	66.96%	70.53%	71.59%	64.76%
Debt-free Net Working Capital to Revenue	168.77%	160.27%	145.56%	130.64%	125.53%	124.37%	97.67%	88.18%	112.74%	99.34%
Net Working Capital to Revenue	168.65%	160.15%	145.45%	130.53%	125.42%	124.27%	97.58%	88.09%	112.66%	99.26%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.88	($0.33)	($0.30)	($0.13)	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)
Adjusted Weighted Average Basic Shares Outstanding	21.15M	20.70M	22.51M	22.70M	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M
Adjusted Diluted Earnings per Share	$0.87	($0.32)	($0.30)	($0.13)	($0.20)	($0.29)	($0.34)	($0.26)	($0.34)	($0.70)
Adjusted Weighted Average Diluted Shares Outstanding	21.30M	20.95M	22.51M	22.70M	22.76M	22.68M	22.82M	23.15M	23.17M	23.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	22.89M	22.99M	23.33M	23.35M	23.35M	23.55M	23.83M	24.21M	24.22M	24.29M
Normalized Net Operating Profit after Tax (NOPAT)	-2.35	-5.82	-6.01	-3.91	-2.47	-5.65	-6.81	-3.97	-3.90	-9.84
Normalized NOPAT Margin	-6.71%	-18.77%	-19.04%	-9.88%	-6.17%	-15.01%	-15.23%	-7.51%	-7.14%	-18.68%
Pre Tax Income Margin	41.19%	-25.48%	-23.36%	-8.31%	-9.36%	-18.35%	-23.13%	-11.45%	-16.74%	-31.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	21.33	0.00	0.00	-10.18	-177.19	0.00	-15.23	-22.17	-1.51	-11.44
NOPAT to Interest Expense	-12.66	0.00	0.00	-13.30	-150.27	0.00	-10.68	-15.20	-1.07	-7.46
EBIT Less CapEx to Interest Expense	19.80	0.00	0.00	-29.31	-321.24	0.00	-25.37	-47.78	-1.89	-11.24
NOPAT Less CapEx to Interest Expense	-14.20	0.00	0.00	-32.43	-294.31	0.00	-20.83	-40.81	-1.45	-7.26
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

OrthoPediatrics Corp (KIDS) has shown topline momentum in late 2024 with strong gross margins and ample liquidity, but profitability remains a challenge as quarterly net losses persist and operating cash flow is still negative. The company also used growth financing in 2024 to fund acquisitions and expansion.

Q4 2024 revenue reached about $52.7 million, up from roughly $37.6 million in Q4 2023 (roughly +39% year over year).
Gross margin across 2024 quarters remained strong, generally around 70% or higher (e.g., Q2 2024 ~77%, Q3 2024 ~74%), indicating solid product margins.
Liquidity is robust in recent quarters, with Q3 2024 current assets around $248.3 million and current liabilities around $34.6 million (roughly a 7x current ratio).
Significant financing inflows in Q3 2024 (~$58.5 million) provided capital flexibility to support growth initiatives and acquisitions.
Acquisitions in 2024 added to the asset base (around $25 million in Q3 2024 and about $22.6 million in Q4 2024), reflecting growth investments.
Goodwill (~$91 million) and intangible assets (~$85 million by 2024) contribute to a larger noncurrent asset base, which could carry impairment risk if growth slows.
Cash flows from investing activities were negative in 2024 due to acquisitions and investments (e.g., net cash from continuing investing activities around -$2.41 million in Q4 2024), balancing ongoing profitability considerations.
Net income in Q4 2024 was a loss of about $16.07 million, continuing a pattern of quarterly losses.
Operating income remained negative in Q4 2024 (-$14.06 million) and across recent quarters, highlighting ongoing profitability challenges.
Earnings per share remained negative in Q4 2024, with basic and diluted EPS around -$0.70 per share.

05/08/26 05:00 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About OrthoPediatrics' Financials

When does OrthoPediatrics' financial year end?

According to the most recent income statement we have on file, OrthoPediatrics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has OrthoPediatrics' net income changed over the last 2 years?

OrthoPediatrics' net income appears to be on an upward trend, with a most recent value of -$37.82 million in 2024, falling from $1.26 million in 2022. The previous period was -$20.97 million in 2023. Check out OrthoPediatrics' forecast to explore projected trends and price targets.

What is OrthoPediatrics' operating income?

OrthoPediatrics' total operating income in 2024 was -$35.01 million, based on the following breakdown:

Total Gross Profit: $148.60 million
Total Operating Expenses: $183.61 million

How has OrthoPediatrics' revenue changed over the last 2 years?

Over the last 2 years, OrthoPediatrics' total revenue changed from $122.29 million in 2022 to $204.73 million in 2024, a change of 67.4%.

How much debt does OrthoPediatrics have?

OrthoPediatrics' total liabilities were at $118.64 million at the end of 2024, a 92.2% increase from 2023, and a 141.7% increase since 2022.

How much cash does OrthoPediatrics have?

In the past 2 years, OrthoPediatrics' cash and equivalents has ranged from $8.99 million in 2022 to $43.82 million in 2024, and is currently $43.82 million as of their latest financial filing in 2024.

How has OrthoPediatrics' book value per share changed over the last 2 years?

Over the last 2 years, OrthoPediatrics' book value per share changed from 16.54 in 2022 to 14.64 in 2024, a change of -11.5%.

Related Companies

Financial statements for NASDAQ:KIDS last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OrthoPediatrics (KIDS) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About OrthoPediatrics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OrthoPediatrics (KIDS) Financials

Annual Income Statements for OrthoPediatrics

Quarterly Income Statements for OrthoPediatrics

Annual Cash Flow Statements for OrthoPediatrics

Quarterly Cash Flow Statements for OrthoPediatrics

Annual Balance Sheets for OrthoPediatrics

Quarterly Balance Sheets for OrthoPediatrics

Annual Metrics And Ratios for OrthoPediatrics

Quarterly Metrics And Ratios for OrthoPediatrics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About OrthoPediatrics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools